Faculty-Invented Oxygen Delivery Device, Sovant™, Receives FDA Approval
The Department of Anesthesiology is proud to share that Sovant™, a groundbreaking oxygen delivery system developed by faculty-founded company Dynasthetics, has officially received FDA approval.
Designed to modernize an approach that hasn’t changed in over 75 years, Sovant™ offers a dynamic and intelligent method for administering supplemental oxygen—adapting in real time to patients’ ventilatory needs during sedation. Unlike traditional systems that continuously deliver oxygen regardless of patient breathing, Sovant™ conserves resources and enhances safety by pausing oxygen flow during exhalation.
The device also introduces a suite of monitoring features to improve clinical awareness and patient outcomes:
- A ventilatory pressure waveform that displays inhalation and exhalation
- Audible cues and alarms for respiratory changes or dislodged equipment
- Enhanced accuracy in measuring exhaled carbon dioxide
“Sovant™ gives clinicians a better, smarter way to understand how their patients are breathing,” said Dr. Derek Sakata, a faculty member and co-founder of Dynasthetics. “It’s about improving patient safety, conserving oxygen, and reducing cognitive load for providers—all while advancing sedation care.”
The approval process involved rigorous safety and efficacy testing as well as post-market planning. With FDA clearance secured, Sovant™ is now poised to improve care in procedural sedation, emergency medicine, inpatient oxygen therapy, and beyond.
Congratulations to the Dynasthetics team and our faculty innovators for this major achievement in advancing respiratory care!